Multiple Myeloma Stem Cell Therapy Development

Multiple myeloma is a cancer of plasma cells. Multiple myeloma (MM) is a haematological malignancy characterized by the accumulation of clonal plasma cells in the bone marrow. Although novel therapeutic strategies have prolonged survival of patients, the disease remains difficult to treat with a high risk of relapse. Stem cell transplantation is a common treatment for multiple myeloma. Therefore, CD BioSciences has launched multiple myeloma stem cell therapy development services.

Overview of Multiple Myeloma

The blood cancer multiple myeloma is one of these. The bone marrow, the pliable tissue found inside bones, is where it begins. The body creates blood cells in this location, including a particular subset known as plasma cells. In the bone marrow, these cells can proliferate out of control and stifle the normal, healthy ones. They become a tumor when they accumulate. As the name suggests, the condition can result in multiple tumors.

Myeloma Stem Cell

Myeloma stem cells have self-renewal capabilities through signaling pathways like Hedgehog, Wnt/-catenin, Notch, and Bmi. They share similar signaling pathways and signaling molecules with normal stem cells. Myeloma and unrestricted tumor cell proliferation result from these signaling pathways becoming abnormal.

• Clinical Translation of Myeloma Stem Cell
  The persistent population of myeloma stem cells is thought to be possibly related to the failure of multiple myeloma treatment. A straightforward and efficient way to treat MM and overcome drug resistance is provided by myeloma stem cell theories. More research-related experiments are currently being conducted.

Dormant plasma cells or memory B-cells should acquire a growth advantage as the first stage in the development of myeloma. After differentiating from CD38-negative post-GC cells, normal plasma cells (PC) start to express the signature protein CD38, but they can still express CD19. Myeloma cells (malignant PC) do not express CD19, which is a striking contrast. Additionally, during the malignant transformation, the expression levels of CD45 and CD56 change in a positive and negative manner, respectively. The disease condition is by definition monoclonal gammopathy of undetermined significance (MGUS) when the proportion of malignant PC (M) is less than 10% of bone marrow mononuclear cells. When malignant PC represents more than 10% of the bone, multiple myeloma (MM) is diagnosed.

Alterations in surface markers during myeloma cell formation. (Yusuke Furukawa. et al. 2015)

Our Services

CD BioSciences offers multiple myeloma stem cell therapy development services. Currently, there is no medical treatment that can completely cure multiple myeloma. The advent of stem cells offers hope for a cure for this disease. Research targeting stem cell transplantation and myeloma stem cells can positively contribute to the treatment of the disease. Based on our professional experimental team, we can help you to solve the problems encountered in multiple myeloma stem cell therapy development together.

As a pioneer in biotechnology, CD BioSciences has grown into one of the largest independent biotechnology companies in the world. CD BioSciences is committed to providing professional and efficient service to our customers around the world. If you are interested in our service, please contact us.

References

1. Hajek, R. et al. (2013). Myeloma stem cell concepts, heterogeneity and plasticity of multiple myeloma. British Journal of Haematology. 163(5).
2. Yusuke Furukawa. et al. (2015). Molecular pathogenesis of multiple myeloma. British Journal of Haematology. 20(3)：413-22.